Reported Friday, Sep 25 - 7:07am EDT (TheFly subscription required to read more.)

C4 Therapeutics (NASDAQ:CCCC) presented promising Phase 1 clinical trial data for cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma. The trial showed 50% overall response rate (ORR) at the highest dose level (100 µg) and 40% ORR at the 75 µg dose level in heavily pre-treated patients.Key highlights include a median duration of response of 9.3 months across all dose levels, with median duration not yet reached at the two highest doses. The drug demonstrated a favorable safety profile with no treatment discontinuations and minimal dose reductions. The study involved 72 patients who had received a median of seven prior therapies, with 75% having previous BCMA-targeted therapy exposure.C4T plans to pursue two distinct opportunities for accelerated approval through a Phase 2 trial in Q1 2026 for fourth-line therapy and a Phase 1b trial in Q2 2026 to evaluate combination with BCMA BiTE in second-line therapy.

Click to view the official SEC document.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.

If approved, C4's cemsidomide could become the best-in-class IKZF1/3 degrader available for multiple myeloma over pomalidomide.

Reported Thursday, Jun 11 - 7:59am EDT (TheFly subscription required to read more.)

Reported Wednesday, Mar 25 - 7:24am EDT (TheFly subscription required to read more.)

Reported Sunday, Sep 21 - 10:53am EDT (TheFly subscription required to read more.)

Reported Wednesday, Sep 3 - 7:06am EDT (TheFly subscription required to read more.)

C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading. As of February 16, 2026, all of the analysts who cover C4 Therapeutics, Inc.

C4 Therapeutics (Nasdaq: CCCC) reported first quarter 2026 revenue of $6.2 million, down from $7.2 million a year earlier, and a net loss of $25.1 million or $0.20 per share.The company advanced multiple myeloma degrader cemsidomide with ongoing Phase 2 MOMENTUM and Phase 1b elranatamab combination trials and plans another Phase 1b combo study in 1H 2027. A new Roche collaboration on degrader-antibody conjugates brought a $20 million upfront payment. Cash, cash equivalents and marketable securities were $268.3 million on March 31, 2026, with funding expected to last through year-end 2028. C4 Therapeutics decided not to advance CFT8919 for EGFR-mutated NSCLC outside Greater China.

C4 Therapeutics (Nasdaq: CCCC) announced the first patient has been dosed in a Phase 1b trial of oral cemsidomide plus dexamethasone with FDA-approved elranatamab (ELREXFIO) for relapsed/refractory multiple myeloma.The open-label, multicenter study will enroll up to 54 patients, test 50/75/100 µg cemsidomide doses, assess safety/tolerability as the primary endpoint, and aims to report Phase 1b data in mid-2027. Pfizer supplies elranatamab at no cost per the collaboration.

C4 Therapeutics (Nasdaq: CCCC) reported 2025 results and program progress on Feb 26, 2026. Key items: cemsidomide moved into a Phase 2 MOMENTUM trial with first patient dosed and a recommended Phase 2 dose of 100 µg. Cash, cash equivalents and marketable securities were $297.1M at Dec 31, 2025, providing runway to the end of 2028. Company raised $125M in October 2025 and earned a $2M Biogen milestone; Phase 1b combo trial with elranatamab is on track for Q2 2026.

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds

C4 Therapeutics (NASDAQ:CCCC) reported Q2 2025 financial results and business updates, highlighting progress in its targeted protein degradation pipeline. The company's lead drug cemsidomide demonstrated promising Phase 1 results with 40% overall response rate (ORR) at 75 µg dose and 50% ORR at 100 µg dose in multiple myeloma patients.Financial results showed revenue of $6.5M (down from $12.0M in Q2 2024), with a net loss of $26.0M. The company maintains a strong financial position with $223.0M in cash, extending runway to mid-2027. A milestone payment of $1M was earned from the Merck KGaA collaboration focused on KRAS family projects.Following a productive FDA Type C meeting, C4T plans to initiate registrational development of cemsidomide in early 2026, focusing on multiple myeloma over non-Hodgkin's lymphoma for strategic reasons.

C4 Therapeutics (NASDAQ: CCCC) reported Q1 2025 financial results and key developments. The company's lead drug cemsidomide showed promising results in multiple myeloma treatment, achieving a 50% overall response rate at 100 µg dose and 40% ORR at 75 µg dose. Notably, one patient achieved minimal residual disease negative complete response. The company has completed Phase 1 dose escalation for multiple myeloma and expects FDA feedback by mid-2025. C4T reported $234.7 million in cash and equivalents, providing runway into 2027. Q1 2025 revenue was $7.2 million, up from $3.0 million in Q1 2024, while net loss decreased to $26.3 million ($0.37 per share) from $28.4 million. The company is prioritizing cemsidomide development while seeking partnership opportunities for its BRAF program.

Cemsidomide achieved 44% response rate in PTCL while company boosted revenue by 71% to $35.6M with $267.3M cash runway into 2027, despite ongoing losses.

This Hematology update highlights expanded European approval for Opdivo plus AVD in frontline advanced classical Hodgkin lymphoma, long-term Phase 3 efficacy data for Scemblix in newly diagnosed CML, and emerging biomarker insights in AML. Additional updates include iopofosine activity in Waldenström macroglobulinemia, iadademstat and cemsidomide clinical results, epcoritamab subgroup findings in follicular lymphoma, and the first-in-human clinical approval of the TCX-001 CAR-T program for AML and CLL.

Hematology Update: Cemsidomide–Elranatamab Combo, Ziftomenib AML Trial, Fast Track CAR T & More From C4–Pfizer’s cemsidomide–elranatamab partnership in myeloma to […] The post Hematology Weekly News – October 6th 2025 appeared first on LucidQuest Ventures.